GlassScriptPhysician profile
Amer Abdulghafoor
NPI 1619401718
$2,789.76
in general payments reported to CMS, 2019-2025
20 companies · $2,382 in 2025
The $2,382 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $408 · 2025: $2,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,789.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $961.01 | 2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $660.73 | 2024-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $267.24 | 2024-2025 | Pifeltro, Delstrigo, Capvaxive |
| Theratechnologies INC. | $229.72 | 2024-2025 | Trogarzo, Egrifta |
| Exact Sciences Corporation | $99.28 | 2024-2025 | Cologuard Collection Kit |
| Napo Pharmaceuticals INC | $86.35 | 2024-2025 | Mytesi |
| Seqirus USA INC | $71.52 | 2024-2025 | Fluad, Flucelvax |
| Emd Serono, INC. | $60.84 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $44.14 | 2024-2025 | Gvoke Hypopen |
| Novo Nordisk INC | $44.02 | 2025 | Wegovy |
| Indivior INC. | $41.86 | 2025 | Sublocade |
| Glaxosmithkline, LLC. | $39.75 | 2025 | Arexvy, Shingrix, Bexsero |
| Pfizer INC. | $37.68 | 2024-2025 | |
| Abbvie INC. | $24.68 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $23.57 | 2025 | Cobenfy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $23.46 | 2025 | Secuado |
| Lilly USA, LLC | $22.95 | 2024 | Zepbound, Mounjaro |
| Corium, LLC | $18.65 | 2025 | Azstarys |
| Braeburn INC. | $18.20 | 2025 | Brixadi |
| Organon LLC | $14.11 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Abdulghafoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.